Identifying who benefits from a specific immune therapy in Type 1 diabetes
Development of a Predictive Response Signature to Anti-Thymocyte Globulin in Type 1 Diabetes
['FUNDING_CAREER'] · UNIVERSITY OF FLORIDA · NIH-11082344
This study is looking at how well a treatment called anti-thymocyte globulin (ATG) can help people with Type 1 diabetes keep their insulin-producing cells working, and it aims to find out which patients are most likely to benefit from this treatment by analyzing past trial samples.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF FLORIDA (nih funded) |
| Locations | 1 site (GAINESVILLE, UNITED STATES) |
| Trial ID | NIH-11082344 on ClinicalTrials.gov |
What this research studies
This research focuses on Type 1 diabetes, an autoimmune condition where the immune system attacks insulin-producing cells in the pancreas. The study aims to develop a predictive response signature for a treatment called anti-thymocyte globulin (ATG), which has shown promise in preserving pancreatic function in some patients. By analyzing biological samples from previous clinical trials, researchers will identify markers that can predict which patients are likely to respond positively to ATG therapy. This approach aims to improve patient selection for future clinical trials and enhance treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals recently diagnosed with Type 1 diabetes who are considering immunotherapy options.
Not a fit: Patients with long-standing Type 1 diabetes or those who do not meet the criteria for recent-onset disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment strategies for individuals with Type 1 diabetes.
How similar studies have performed: Previous research has shown that low-dose ATG can preserve pancreatic function in some patients, indicating potential for success in this novel approach.
Where this research is happening
GAINESVILLE, UNITED STATES
- UNIVERSITY OF FLORIDA — GAINESVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JACOBSEN, LAURA — UNIVERSITY OF FLORIDA
- Study coordinator: JACOBSEN, LAURA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases, autoimmune disorder, autoimmunity disease